Emergent Biosolutions Inc (EBS)

Currency in USD
10.700
-0.130(-1.20%)
Closed·
10.560-0.140(-1.31%)
·
Earnings results expected in 8 days
EBS is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
10.65011.080
52 wk Range
4.02014.060
Key Statistics
Prev. Close
10.83
Open
10.79
Day's Range
10.65-11.08
52 wk Range
4.02-14.06
Volume
358.48K
Average Volume (3m)
819.18K
1-Year Change
28.2974%
Book Value / Share
10.92
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
EBS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
13.500
Upside
+26.17%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Emergent Biosolutions Inc Company Profile

Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; Botulism Antitoxin Heptavalent for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Trobigard, an atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Employees
900

Emergent Biosolutions Inc Earnings Call Summary for Q2/2025

  • Q2 2025 EPS of $0.16 beat -$0.10 forecast, but revenue of $141M missed $174M estimate; stock dipped 1.15% after hours to $6.03
  • Operating expenses reduced 53% YoY; net leverage improved from 9.9x to 1.9x; NARCAN nasal spray revenue up 50% from Q1
  • 2025 revenue guidance $765M-$835M; adjusted EBITDA forecast $175M-$200M; focus on government collaborations and international growth
  • CEO highlighted progress on turnaround plan and value in addressing public health challenges; aims for NARCAN in 'every first aid kit'
  • Analysts questioned NARCAN pricing stability and synthetic opioid challenges; company expects MCM contract modifications
Last Updated: 2025-08-07, 04:06 a/m
Read Full Transcript

Compare EBS to Peers and Sector

Metrics to compare
EBS
Peers
Sector
Relationship
P/E Ratio
7.4x17.9x−0.5x
PEG Ratio
0.060.040.00
Price/Book
1.0x2.1x2.6x
Price / LTM Sales
0.7x2.0x3.3x
Upside (Analyst Target)
25.6%26.6%46.0%
Fair Value Upside
Unlock7.3%5.4%Unlock

Analyst Ratings

2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 13.500
(+26.17% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
H.C. Wainwright
Buy15.00+40.19%-MaintainSep 22, 2025
H.C. Wainwright
Buy15.00+40.19%-MaintainSep 16, 2025
H.C. Wainwright
Buy15.00+40.19%-MaintainSep 11, 2025
H.C. Wainwright
Buy15.00+40.19%-MaintainSep 03, 2025
H.C. Wainwright
Buy15.00+40.19%-MaintainMar 04, 2025

Earnings

Latest Release
Oct 29, 2025
EPS / Forecast
1.06 / 0.0467
Revenue / Forecast
231.10M / 203.67M
EPS Revisions
Last 90 days

EBS Income Statement

People Also Watch

72.31
SYF
+1.30%
14.310
AUPH
+0.56%
24.640
CPRX
+1.27%
21.68
SM
+1.03%
7.210
CRMD
-1.77%

FAQ

What Is the Emergent Biosolutions (EBS) Stock Price Today?

The Emergent Biosolutions stock price today is 10.700

What Stock Exchange Does Emergent Biosolutions Trade On?

Emergent Biosolutions is listed and trades on the New York Stock Exchange.

What Is the Stock Symbol for Emergent Biosolutions?

The stock symbol for Emergent Biosolutions is "EBS."

What Is the Emergent Biosolutions Market Cap?

As of today, Emergent Biosolutions market cap is 561.960M.

What Is Emergent Biosolutions's Earnings Per Share (TTM)?

The Emergent Biosolutions EPS (TTM) is 1.351.

When Is the Next Emergent Biosolutions Earnings Date?

Emergent Biosolutions will release its next earnings report on Feb 26, 2026.

From a Technical Analysis Perspective, Is EBS a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Emergent Biosolutions Stock Split?

Emergent Biosolutions has split 0 times.

How Many Employees Does Emergent Biosolutions Have?

Emergent Biosolutions has 900 employees.

What is the current trading status of Emergent Biosolutions (EBS)?

As of Feb 18, 2026, Emergent Biosolutions (EBS) is trading at a price of 10.700, with a previous close of 10.830. The stock has fluctuated within a day range of 10.650 to 11.080, while its 52-week range spans from 4.020 to 14.060.

What Is Emergent Biosolutions (EBS) Price Target According to Analysts?

The average 12-month price target for Emergent Biosolutions is USD13.500, with a high estimate of USD15 and a low estimate of USD12. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +26.17% Upside potential.

What Is the EBS After Hours Price?

EBS's last after hours stock price is 10.560, the stock has decreased by -0.140, or -1.310%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.